Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Breast 1

Conditions

Lung Neoplasms 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 12Gemcitabine 9Cetuximab 7Psychiatric Rehabilitation 6Paclitaxel 6Magnetic Resonance Spectroscopy 6Fluorouracil 6Early Intervention, Educational 6Cisplatin 6cediranib 5Leucovorin 5Carboplatin 5sargramostim 4Standard of Care 4Oxaliplatin 4Methods 4Erlotinib Hydrochloride 4Docetaxel 4Cyclophosphamide 4selpercatinib 3aldesleukin 3adagrasib 3Trastuzumab 3Therapeutics 3Pemetrexed 3Nivolumab 3Irinotecan 3Fluorodeoxyglucose F18 3Bortezomib 3Bevacizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colonic Neoplasms × devimistat × Thoracic × Clear all
NCT01832857 2016-12-29

Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients

Cornerstone Pharmaceuticals

Phase 2 Terminated
7 enrolled
BreastGastrointestinalThoracic

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡